MARX Biotech Co., Ltd. (TPEX:7731)
6.03
-0.02 (-0.33%)
Apr 24, 2025, 1:38 PM CST
MARX Biotech Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 74.67 | 152.83 | 27.73 | 0.18 |
Short-Term Investments | 3.5 | - | - | - |
Cash & Short-Term Investments | 78.17 | 152.83 | 27.73 | 0.18 |
Cash Growth | -48.85% | 451.08% | 15479.78% | - |
Accounts Receivable | 120.02 | 98.42 | 54.95 | - |
Other Receivables | 3.92 | 4.62 | - | - |
Receivables | 123.94 | 103.04 | 54.95 | - |
Inventory | 164.31 | 70 | 12 | - |
Prepaid Expenses | 35.93 | 13.98 | 0.83 | - |
Other Current Assets | 4.95 | 3.19 | 0.56 | - |
Total Current Assets | 407.3 | 343.04 | 96.07 | 0.18 |
Property, Plant & Equipment | 217.19 | 4.26 | 4.73 | - |
Long-Term Investments | - | - | - | 13.5 |
Goodwill | - | 5.37 | - | - |
Other Intangible Assets | 91.61 | 30.1 | - | - |
Long-Term Deferred Tax Assets | 6.56 | 4.92 | 1.94 | 0.09 |
Other Long-Term Assets | 8.54 | 7.15 | 0.45 | 0.03 |
Total Assets | 731.2 | 394.85 | 103.19 | 13.8 |
Accounts Payable | 88.88 | 23.72 | 5.26 | - |
Accrued Expenses | - | 39.77 | 12.98 | 0.5 |
Short-Term Debt | 98 | - | 10 | - |
Current Portion of Long-Term Debt | 5.27 | - | - | - |
Current Portion of Leases | 3.9 | 1.26 | 2.97 | - |
Current Income Taxes Payable | - | - | 3.41 | - |
Current Unearned Revenue | 40.26 | 25.08 | 2.28 | - |
Other Current Liabilities | 72.12 | 11.2 | 4.6 | 0.16 |
Total Current Liabilities | 308.43 | 101.04 | 41.5 | 0.66 |
Long-Term Debt | 165.04 | - | - | - |
Long-Term Leases | 5.11 | 0.62 | 0.87 | - |
Long-Term Deferred Tax Liabilities | 1.38 | 0.2 | 0.08 | - |
Total Liabilities | 479.95 | 101.86 | 42.45 | 0.66 |
Common Stock | 126.5 | 124.51 | 40.8 | 8.05 |
Additional Paid-In Capital | 220.48 | 186.03 | 17.98 | 3.21 |
Retained Earnings | -95.73 | -17.55 | 1.95 | 1.89 |
Shareholders' Equity | 251.25 | 292.99 | 60.73 | 13.14 |
Total Liabilities & Equity | 731.2 | 394.85 | 103.19 | 13.8 |
Total Debt | 277.32 | 1.88 | 13.84 | - |
Net Cash (Debt) | -199.15 | 150.94 | 13.89 | 0.18 |
Net Cash Growth | - | 986.39% | 7705.62% | - |
Net Cash Per Share | -0.40 | 0.36 | 0.04 | 0.01 |
Filing Date Shares Outstanding | 498.92 | 498.06 | 163.21 | 32.18 |
Total Common Shares Outstanding | 498.92 | 498.06 | 163.21 | 32.18 |
Working Capital | 98.87 | 242.01 | 54.57 | -0.48 |
Book Value Per Share | 0.50 | 0.59 | 0.37 | 0.41 |
Tangible Book Value | 159.64 | 257.52 | 60.73 | 13.14 |
Tangible Book Value Per Share | 0.32 | 0.52 | 0.37 | 0.41 |
Machinery | - | 2.7 | 1.03 | - |
Construction In Progress | - | 0 | 0.02 | - |
Leasehold Improvements | - | 1.1 | 0.44 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.